A phase I trial of the dual kinase inhibitor GW572016 [lapatinib] in combination with topotecan in patients with advanced solid malignancies.

Trial Profile

A phase I trial of the dual kinase inhibitor GW572016 [lapatinib] in combination with topotecan in patients with advanced solid malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2011

At a glance

  • Drugs Lapatinib; Topotecan
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 26 May 2009 Actual end date (Nov 2006) added as reported by ClinicalTrials.gov.
    • 26 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Aug 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top